Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -4.17% | -23.33% | -1.29% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 400K | Sales 2025 * | 250K | Capitalization | 33.84M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -40M | EV / Sales 2024 * | 84.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 135 x |
P/E ratio 2024 * |
-2.3
x | P/E ratio 2025 * |
-2.4
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.31% |
Latest transcript on VYNE Therapeutics Inc.
1 day | -4.17% | ||
1 week | -23.33% | ||
Current month | -25.08% | ||
1 month | +19.79% | ||
3 months | +22.99% | ||
6 months | -15.44% | ||
Current year | -1.29% |
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 20-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 20-09-09 |
Steven Basta
BRD | Director/Board Member | 59 | 14-12-31 |
Anthony Bruno
BRD | Director/Board Member | 68 | 20-02-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 2.3 | -4.17% | 11,091 |
24-04-17 | 2.4 | -0.83% | 31,265 |
24-04-16 | 2.42 | -5.84% | 33,106 |
24-04-15 | 2.57 | -7.22% | 58,530 |
24-04-12 | 2.77 | -7.67% | 28,561 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.29% | 33.84M | |
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+6.25% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- VYNE Stock